By Mill Chart
Last update: Jul 31, 2025
Nature’s Sunshine Products, Inc. (NASDAQ:NATR) reported its second-quarter 2025 earnings, delivering mixed results compared to analyst expectations. The company, a manufacturer of herbal and nutritional supplements, posted revenue of $114.75 million, falling short of the consensus estimate of $117.05 million. However, earnings per share (EPS) came in at $0.35, significantly above the estimated $0.16.
While the press release did not provide a detailed forward-looking outlook, analysts currently expect Q3 2025 revenue to reach $119.02 million, with EPS projected at $0.19. For the full year, sales estimates stand at $468.35 million, with revenue growth pegged at $0.80 per share.
The lack of guidance from management leaves investors reliant on these external estimates, which may contribute to ongoing uncertainty in the stock’s performance. The recent downward trend in share price (-5.78% over the past week) suggests that despite the EPS beat, concerns linger—possibly related to the revenue shortfall or broader market conditions affecting the supplements sector.
Nature’s Sunshine operates across four geographic segments (Asia, Europe, North America, and Latin America), with a product portfolio spanning over 800 items. The company’s reliance on independent consultants for distribution adds variability to sales execution, which may explain the revenue volatility.
For a deeper dive into historical earnings and future estimates, review the full earnings and estimates breakdown here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
NASDAQ:NATR (8/21/2025, 11:07:13 AM)
16.57
+0.08 (+0.49%)
Find more stocks in the Stock Screener